Curative Biotechnology is a development-stage biotech company that in-licenses early-stage drug and medical device assets from government research institutions, advances them to early clinical milestones, and then aims to out-license or sell them to larger pharmaceutical companies. The company has no revenue and has never commercialized a product. Its entire active focus is a single program: reformulated metformin eye drops to treat dry age-related macular degeneration (AMD), a large indication with no currently approved treatments. The technology is licensed from the National Eye Institute at the NIH, and the compound repurposes metformin — one of the world's most widely used diabetes drugs — as a topical eye drop targeting cellular dysfunction in the retinal pigment epithelium. Curative Biotechnology has completed animal toxicology studies and is targeting an IND submission to the FDA in Q1 2026. If approved, the clinical trial would be run by the NEI under a cooperative agreement, with Curative Biotechnology supplying the drug and contributing up to $115,000 toward trial costs. The company also holds two inactive, unfunded programs — an immunotherapy for late-stage rabies and an antibody-drug conjugate for glioblastoma — both licensed from government research institutions. Curative Biotechnology operates with three employees on a fully outsourced model, using CROs, CMOs, and external consultants. The company funds operations entirely through equity and debt issuances and is pursuing an IPO to raise approximately $10M to repay existing debt and advance the AMD program.